BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/6/2019 6:23:58 AM | Browse: 1206 | Download: 2039
 |
Received |
|
2019-04-06 07:51 |
|
Peer-Review Started |
|
2019-04-08 01:16 |
|
To Make the First Decision |
|
2019-04-17 00:48 |
|
Return for Revision |
|
2019-04-17 02:33 |
|
Revised |
|
2019-05-02 06:53 |
|
Second Decision |
|
2019-05-17 09:11 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-05-18 12:40 |
|
Articles in Press |
|
2019-05-18 12:40 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-07-04 07:10 |
|
Publish the Manuscript Online |
|
2019-07-06 06:23 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Daniel Neureiter, Sebastian Stintzing, Tobias Kiesslich and Matthias Ocker |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Matthias Ocker, MD, Professor, Translational Medicine Oncology, Bayer AG, Muellerstrasse 178, Berlin 13353, Germany. matthias.ocker@bayer.com |
| Key Words |
Liver cancer; Immunotherapy; Checkpoint inhibitors; Targeted therapy; Mouse model; Biomarker; Next-generation sequencing; Non-alcoholic steatohepatitis; Fibrosis; Clinical trial |
| Core Tip |
Treatment of advanced hepatocellular carcinoma still represents an unmet medical need. Novel therapeutic options comprise new tyrosine kinase inhibitors, epigenetic modifiers and increasingly also cell therapy and immune checkpoint inhibitors and combinations of those modalities. Development of better drugs is closely linked to improved preclinical and animal models and has to be accompanied by the implementation of predictive biomarkers, which is still lacking for hepatocellular carcinoma. The current status of these aspects is reviewed in this manuscript. |
| Publish Date |
2019-07-06 06:23 |
| Citation |
Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i25/3136.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i25.3136 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
